HMD’s Syringes are mainstay of India’s globally acclaimed Mass COVID Vaccination

New Delhi: Hindustan Syringes & Medical Devices Ltd (HMD) has expressed happiness over its part in India’s massive COVID vaccination program which has become role model for the world.

Congratulating Government of India for the feat, the manufacturer has saidit feels proud for shouldering the responsibility with the government. HMD, one of the leading manufacturers of Disposable Syringes in the World and possibly the largest for Auto Disable syringes, has supplied 471.35 million pcs to GoI by Sep end to help vaccinate 642.5 million people.

‘India’s vaccination drive has been a role model for the world. We congratulate the Indian Government & we are glad we could shoulder the responsibilities with the Govt. for the success of India’s massive vaccination campaign, while balancing needs for seasonal spike of Dengue & Typhoid” said Mr. Rajiv Nath, Managing Director of Hindustan Syringes & Medical Devices Ltd.

“To ensure there is no shortage of syringes, HMD has preponed the supply commitments to Ministry of Health and Family Welfare and against 442.5 million pcs committed by Sep, HMD has already supplied 471.35 million pcs. An additional 13 million pcs are also on the way. Govt. of India has entrusted HMD with a new order of 132.5 mn pcs which also HMD accepted” said Mr. Rajiv Nath.

“In our utmost endeavour to make India Covid syringe surplus, in August HMD has achieved production capacity of over 1 billion AD syringes for Covid vaccination per year, helping make India Atmanirbhar in syringe manufacturing. Presently HMD is producing more than 4.2 lakh syringes of various types per hour at our factories spread over 11 acres in Faridabad industrial district in Haryana.” Stated Mr. Rajiv Nath.

“In line with PM Modi’s plans to resume export of surplus COVID-19 vaccines in the fourth quarter of 2021 in order to fulfill the commitment of India towards COVAX, we at HMD are confident that India will also be in a position to export Covid vaccine syringes as part of vaccine Maitri to fulfill India’s commitment towards the world for the collective fight against COVID-19. No One is Safe until Everyone is Safe” Shared Mr. Nath.

Mr. Nath further stated that HMD is in a position & well equipped to export non-covid syringes mainly for children for Yellow Fever or Measles, Hepatitis B, Pentavalent or BCG etc. This is India’s and HMD’s ongoing global contractual commitments to support global immunization projects. However, HMD’s top priority right now is to ensure there is no syringe shortage in India to help the Govt. to combat the pandemic.

‘We feel humbled & honored to contribute to The Union Health Ministry’s plans to celebrate India administering 1 billion Covid vaccine doses by early October’ said the elated Mr. Rajiv Nath.

Highlighting the role played by HMD to help in vaccinating India against Covid, Mr. Nath shared “Amidst the alarming covid situation, our manufacturing plants were operational 24/7 and acted as a backbone to the Indian Healthcare sector and the frontline workers.  In April 2020 itself, we started to rapidly ramped up HMD’s capacity and re-engineered the standard Disposables Syringes lines to manufacture in their place Auto Disable Syringe for vaccination. HMD initiated in May investment of over 15 million dollars (approx. 100 Cr Rs.) from their own resources, without govt. support to mass produce Specialty syringes even before Purchase orders were even in sight.”

From 50 Crore (500 mn) pcs per annum capacity of 0.5 ml AD Syringes in June 2020, we increased production rate to 80 Crore (800 mn) pcs per annum in May 2021 & currently we have achieved our target capacity of producing 100 crore (1 billion) Auto Disable syringes per annum to support the massive vaccination campaign to eradicate Covid-19, & next hopefully125 Crore (1.25 bn) pcs per annum by March 2022. HMD has also scaled assorted syringes production to 300 crore (3 bn) and more, in their sincere quest for ensuring no shortages in India.

To help in vaccinating India against Covid, HMD have reserved maximum capacity for India. HMD presently is not accepting any export orders from many overseas potential buyers & to meet the demand, HMD further diverted the supply of 100 million pcs from UNICEF order to GoI from Sept to Dec.

‘HMD had been ensuring continuity of supply chain and its manufacturing plants in its sincere quest to ensure India faces no shortages for its critically needed disposable syringes for covid vaccination. HMD extends full cooperation & support to GoI and will do whatever it needs to produce syringes ahead of schedule to ensure success of India’s massive vaccination campaign.’ Mr. Rajiv Nath concluded.

Related Posts

To Eat or not to Eat, if this Dilemma is ‘Eating’ you, ‘Eat’ this Book

New ‘Bible’ of Nearly ‘Ideal’ Eating hit stands to become Instant Best Seller New Delhi: You are a veritable Hamlet when it comes to the question, to eat or not…

Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

Bharat Mandapam witnessed Spectacle of Crazy Innovations by Maker of Ssi Mantra, Best in class Surgical Robot New Delhi: It was a veritable display of innovative potential and prowess of…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Pak-made illegal cosmetics recovered from Itwari shop

Pak-made illegal cosmetics recovered from Itwari shop

Licences of 20 medical stores suspended after inspections

Licences of 20 medical stores suspended after inspections

Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

HP accounts for 47 inferior drugs in March alert

HP accounts for 47 inferior drugs in March alert